MCID: OVR062
MIFTS: 29

Ovary Serous Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovary Serous Adenocarcinoma

MalaCards integrated aliases for Ovary Serous Adenocarcinoma:

Name: Ovary Serous Adenocarcinoma 12 15
Malignant Ovarian Serous Tumor 12 74
Serous Carcinoma of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5744
NCIt 51 C40025 C7550

Summaries for Ovary Serous Adenocarcinoma

Disease Ontology : 12 An ovary adenocarcinoma that derives from the lining of a cavity that produces a serum-like fluid (a serous cavity).

MalaCards based summary : Ovary Serous Adenocarcinoma, also known as malignant ovarian serous tumor, is related to ovarian serous cystadenocarcinoma and endometrial stromal nodule. An important gene associated with Ovary Serous Adenocarcinoma is KCNMA1 (Potassium Calcium-Activated Channel Subfamily M Alpha 1), and among its related pathways/superpathways is Tyrosine Kinases / Adaptors. The drugs Paclitaxel and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and lymph node, and related phenotype is Decreased substrate adherent cell growth.

Related Diseases for Ovary Serous Adenocarcinoma

Diseases related to Ovary Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ovarian serous cystadenocarcinoma 11.4
2 endometrial stromal nodule 9.9
3 choriocarcinoma 9.9
4 carcinosarcoma 9.9

Symptoms & Phenotypes for Ovary Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Ovary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-2 8.62 EPHA1 EPHB1

Drugs & Therapeutics for Ovary Serous Adenocarcinoma

Drugs for Ovary Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
3
Iodine Approved, Investigational Phase 2 7553-56-2 807
4
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
5
Gemcitabine Approved Phase 2 95058-81-4 60750
6
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
7
Doxil Approved June 1999 Phase 2 31703
8 topoisomerase I inhibitors Phase 2
9 Anti-Bacterial Agents Phase 2
10 Antimetabolites, Antineoplastic Phase 2
11 Albumin-Bound Paclitaxel Phase 2
12 Topoisomerase Inhibitors Phase 2
13 Immunosuppressive Agents Phase 2,Phase 1
14 Immunologic Factors Phase 2,Phase 1
15 Anti-Infective Agents Phase 2,Phase 1
16 Antimetabolites Phase 2
17 Antineoplastic Agents, Phytogenic Phase 2
18 Antibiotics, Antitubercular Phase 2
19 Antimitotic Agents Phase 2
20 Antiviral Agents Phase 2,Phase 1
21 Free Radical Scavengers Phase 2
22 N-monoacetylcystine Phase 2
23 Protective Agents Phase 2
24 cysteine Phase 2
25 Expectorants Phase 2
26 Antioxidants Phase 2
27 Respiratory System Agents Phase 2
28 Antidotes Phase 2
29 CHI3L1 protein, human

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
2 Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Terminated NCT02569957 Phase 2 Topotecan Hydrochloride;Topotecan Hydrochloride;Acetylcysteine
3 Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Withdrawn NCT02470559 Phase 1
4 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Ovary Serous Adenocarcinoma

Genetic Tests for Ovary Serous Adenocarcinoma

Anatomical Context for Ovary Serous Adenocarcinoma

MalaCards organs/tissues related to Ovary Serous Adenocarcinoma:

42
Ovary, T Cells, Lymph Node

Publications for Ovary Serous Adenocarcinoma

Articles related to Ovary Serous Adenocarcinoma:

# Title Authors Year
1
Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. ( 29620581 )
2018
2
Synchronous occurrence of endometrial stromal nodule with papillary serous carcinoma of ovary: report of a case and brief review of literature. ( 25404842 )
2014
3
Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival. ( 24427352 )
2014
4
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. ( 24577588 )
2014
5
Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment. ( 20707961 )
2010

Variations for Ovary Serous Adenocarcinoma

Cosmic variations for Ovary Serous Adenocarcinoma:

9 (show top 50) (show all 1232)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6906506 ZFHX3 ovary,NS,carcinoma,serous carcinoma c.794A>C p.D265A 16:72959352-72959352 0
2 COSM6914646 YES1 ovary,NS,carcinoma,serous carcinoma c.194C>T p.S65F 18:756634-756634 0
3 COSM6969549 XRCC2 ovary,NS,carcinoma,serous carcinoma c.121G>C p.G41R 7:152660701-152660701 0
4 COSM6910241 XPO1 ovary,NS,carcinoma,serous carcinoma c.1072T>C p.S358P 2:61494067-61494067 0
5 COSM3446768 WT1 ovary,NS,carcinoma,serous carcinoma c.1285G>A p.D429N 11:32389123-32389123 0
6 COSM20660 WNK2 ovary,NS,carcinoma,serous carcinoma c.1486G>T p.V496L 9:93239962-93239962 0
7 COSM20717 WNK1 ovary,NS,carcinoma,serous carcinoma c.2829C>T p.Y943Y 12:880028-880028 0
8 COSM1035874 VHL ovary,NS,carcinoma,serous carcinoma c.430G>A p.G144R 3:10146603-10146603 0
9 COSM6923147 TSC2 ovary,NS,carcinoma,serous carcinoma c.4998C>A p.F1666L 16:2087871-2087871 0
10 COSM6975218 TSC2 ovary,NS,carcinoma,serous carcinoma c.1361+1G>A p.? 16:2062601-2062601 0
11 COSM6908724 TSC2 ovary,NS,carcinoma,serous carcinoma c.1217G>A p.R406K 16:2061968-2061968 0
12 COSM6923138 TSC2 ovary,NS,carcinoma,serous carcinoma c.272C>T p.P91L 16:2053388-2053388 0
13 COSM20664 TRRAP ovary,NS,carcinoma,serous carcinoma c.2677C>T p.R893C 7:98921807-98921807 0
14 COSM20653 TRPM7 ovary,NS,carcinoma,serous carcinoma c.1217C>G p.S406C 15:50628237-50628237 0
15 COSM20649 TRIM24 ovary,NS,carcinoma,serous carcinoma c.959T>C p.I320T 7:138529193-138529193 0
16 COSM10660 TP53 ovary,NS,carcinoma,serous carcinoma c.818G>A p.R273H 17:7673802-7673802 0
17 COSM10662 TP53 ovary,NS,carcinoma,serous carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
18 COSM10794 TP53 ovary,NS,carcinoma,serous carcinoma c.796G>A p.G266R 17:7673824-7673824 0
19 COSM10648 TP53 ovary,NS,carcinoma,serous carcinoma c.524G>A p.R175H 17:7675088-7675088 0
20 COSM11073 TP53 ovary,NS,carcinoma,serous carcinoma c.1024C>T p.R342* 17:7670685-7670685 0
21 COSM10654 TP53 ovary,NS,carcinoma,serous carcinoma c.637C>T p.R213* 17:7674894-7674894 0
22 COSM10656 TP53 ovary,NS,carcinoma,serous carcinoma c.742C>T p.R248W 17:7674221-7674221 0
23 COSM10731 TP53 ovary,NS,carcinoma,serous carcinoma c.707A>G p.Y236C 17:7674256-7674256 0
24 COSM44063 TP53 ovary,NS,carcinoma,serous carcinoma c.389T>G p.L130R 17:7675223-7675223 0
25 COSM11392 TP53 ovary,NS,carcinoma,serous carcinoma c.800G>C p.R267P 17:7673820-7673820 0
26 COSM10646 TP53 ovary,NS,carcinoma,serous carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
27 COSM10758 TP53 ovary,NS,carcinoma,serous carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
28 COSM10786 TP53 ovary,NS,carcinoma,serous carcinoma c.949C>T p.Q317* 17:7673579-7673579 0
29 COSM10889 TP53 ovary,NS,carcinoma,serous carcinoma c.536A>G p.H179R 17:7675076-7675076 0
30 COSM44901 TP53 ovary,NS,carcinoma,serous carcinoma c.532C>G p.H178D 17:7675080-7675080 0
31 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 0
32 COSM10870 TP53 ovary,NS,carcinoma,serous carcinoma c.523C>G p.R175G 17:7675089-7675089 0
33 COSM6549 TP53 ovary,NS,carcinoma,serous carcinoma c.743G>T p.R248L 17:7674220-7674220 0
34 COSM44633 TP53 ovary,NS,carcinoma,serous carcinoma c.583A>T p.I195F 17:7674948-7674948 0
35 COSM46471 TP53 ovary,NS,carcinoma,serous carcinoma c.612G>C p.E204D 17:7674919-7674919 0
36 COSM10705 TP53 ovary,NS,carcinoma,serous carcinoma c.586C>T p.R196* 17:7674945-7674945 0
37 COSM10733 TP53 ovary,NS,carcinoma,serous carcinoma c.574C>T p.Q192* 17:7674957-7674957 0
38 COSM10891 TP53 ovary,NS,carcinoma,serous carcinoma c.814G>A p.V272M 17:7673806-7673806 0
39 COSM11524 TP53 ovary,NS,carcinoma,serous carcinoma c.730G>T p.G244C 17:7674233-7674233 0
40 COSM43912 TP53 ovary,NS,carcinoma,serous carcinoma c.395A>C p.K132T 17:7675217-7675217 0
41 COSM11501 TP53 ovary,NS,carcinoma,serous carcinoma c.823T>G p.C275G 17:7673797-7673797 0
42 COSM44205 TP53 ovary,NS,carcinoma,serous carcinoma c.431A>C p.Q144P 17:7675181-7675181 0
43 COSM10659 TP53 ovary,NS,carcinoma,serous carcinoma c.817C>T p.R273C 17:7673803-7673803 0
44 COSM10863 TP53 ovary,NS,carcinoma,serous carcinoma c.833C>T p.P278L 17:7673787-7673787 0
45 COSM11582 TP53 ovary,NS,carcinoma,serous carcinoma c.395A>G p.K132R 17:7675217-7675217 0
46 COSM43963 TP53 ovary,NS,carcinoma,serous carcinoma c.396G>C p.K132N 17:7675216-7675216 0
47 COSM10958 TP53 ovary,NS,carcinoma,serous carcinoma c.797G>T p.G266V 17:7673823-7673823 0
48 COSM11552 TP53 ovary,NS,carcinoma,serous carcinoma c.775G>T p.D259Y 17:7674188-7674188 0
49 COSM43700 TP53 ovary,NS,carcinoma,serous carcinoma c.712T>A p.C238S 17:7674251-7674251 0
50 COSM43616 TP53 ovary,NS,carcinoma,serous carcinoma c.704A>G p.N235S 17:7674259-7674259 0

Expression for Ovary Serous Adenocarcinoma

Search GEO for disease gene expression data for Ovary Serous Adenocarcinoma.

Pathways for Ovary Serous Adenocarcinoma

Pathways related to Ovary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.79 EPHA1 EPHB1

GO Terms for Ovary Serous Adenocarcinoma

Biological processes related to Ovary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.32 EPHA1 EPHB1
2 positive regulation of angiogenesis GO:0045766 9.26 EPHA1 TERT
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.16 EPHA1 EPHB1
4 negative regulation of apoptotic process GO:0043066 8.65 TERT
5 ephrin receptor signaling pathway GO:0048013 8.62 EPHA1 EPHB1

Molecular functions related to Ovary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.26 EPHA1 EPHB1
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.16 EPHA1 EPHB1
3 transmembrane-ephrin receptor activity GO:0005005 8.96 EPHA1 EPHB1
4 ephrin receptor activity GO:0005003 8.62 EPHA1 EPHB1

Sources for Ovary Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....